News
NAVB
0.0010
0.00%
0.0000
Weekly Report: what happened at NAVB last week (0930-1004)?
Weekly Report · 4d ago
Weekly Report: what happened at NAVB last week (0923-0927)?
Weekly Report · 09/30 11:18
Weekly Report: what happened at NAVB last week (0916-0920)?
Weekly Report · 09/23 11:17
Weekly Report: what happened at NAVB last week (0909-0913)?
Weekly Report · 09/16 11:07
Weekly Report: what happened at NAVB last week (0902-0906)?
Weekly Report · 09/09 11:18
Weekly Report: what happened at NAVB last week (0826-0830)?
Weekly Report · 09/02 11:21
Weekly Report: what happened at NAVB last week (0819-0823)?
Weekly Report · 08/26 11:19
Weekly Report: what happened at NAVB last week (0812-0816)?
Weekly Report · 08/19 11:06
Weekly Report: what happened at NAVB last week (0805-0809)?
Weekly Report · 08/12 11:08
Weekly Report: what happened at NAVB last week (0729-0802)?
Weekly Report · 08/05 11:19
Weekly Report: what happened at NAVB last week (0722-0726)?
Weekly Report · 07/29 11:08
Weekly Report: what happened at NAVB last week (0715-0719)?
Weekly Report · 07/22 11:10
Weekly Report: what happened at NAVB last week (0708-0712)?
Weekly Report · 07/15 11:06
Weekly Report: what happened at NAVB last week (0701-0705)?
Weekly Report · 07/08 11:08
Weekly Report: what happened at NAVB last week (0624-0628)?
Weekly Report · 07/01 11:08
Weekly Report: what happened at NAVB last week (0617-0621)?
Weekly Report · 06/24 11:15
Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
Barchart · 06/20 17:02
Weekly Report: what happened at NAVB last week (0610-0614)?
Weekly Report · 06/17 11:07
Weekly Report: what happened at NAVB last week (0603-0607)?
Weekly Report · 06/10 11:09
Weekly Report: what happened at NAVB last week (0527-0531)?
Weekly Report · 06/03 11:12
More
Webull provides a variety of real-time NAVB stock news. You can receive the latest news about Navidea Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About NAVB
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. It has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).